Protein-polymer nanomedicine for Sjogren's Syndrome
用于治疗干燥综合症的蛋白质聚合物纳米药物
基本信息
- 批准号:10662981
- 负责人:
- 金额:$ 59.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-03-01 至 2027-12-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAffinityAmericanAntibodiesArtificial TearsAutoantibodiesAutoimmuneAutoimmune DiseasesB-Cell LymphomasBindingBiodegradationBiodistributionBiologicalBiological AvailabilityBiological ProductsCell Adhesion MoleculesCellsChimeric ProteinsClinicalCombined Modality TherapyComplexCorneaCyclosporineDevelopmentDiseaseDisease modelDoseDrug CarriersDrug KineticsDry Eye SyndromesElastinEngineeringEpithelial CellsEpitheliumExhibitsExtracellular DomainEyeFatigueFemaleFlow CytometryFluoresceinFormulationHistologicHistologyHydroxychloroquineIL17 geneImmune systemImmunosuppressionImmunosuppressive AgentsInbred NOD MiceIndividualInfiltrationInflammationInjectionsIntuitionLacrimal gland structureLinkLiquid substanceLocal TherapyLocalized DiseaseMeasurementMeasuresMethotrexateModelingMolecular TargetNOR MouseNon obeseOralOrganPathogenesisPatientsPeptidesPharmaceutical PreparationsPolymersProductionPropertyProteinsRegimenRiskSalivaSalivarySalivary GlandsSerumSialadenitisSirolimusSiteSjogren&aposs SyndromeStainsSubmandibular glandSymptomsSystemic TherapySystemic diseaseTacrolimus Binding Protein 1ATacrolimus Binding ProteinsTechnologyTestingTherapeuticTimeTissue imagingTopical applicationToxic effectTransition TemperatureTreatment EfficacyTreatment ProtocolsVisceralXerostomiabelimumabclinically relevantcytokinedesigndiabeticeffective therapyefficacy evaluationelastin-binding proteinextracellulareye drynessimmune modulating agentsimmunoregulationimprovedin vitro activityinnovationloss of functionmalemouse modelnanomedicinenanoparticlenanopolymernovelnovel strategiesnovel therapeuticsocular surfacepolypeptidereceptorrituximabsexsubcutaneoussuccesssymptom managementsystemic inflammatory responsetocilizumab
项目摘要
Sjögren's syndrome (SS) is an autoimmune disease manifesting with severe inflammation and loss of function
of lacrimal (LG) and/or salivary (SG) glands, leading to severe dry eye and dry mouth. SS patients also exhibit
extraglandular systemic symptoms including development of autoantibodies, inflammation of visceral organs and
increased risk of B-cell lymphoma. Pathogenesis is complex and involves interplay between the activated
immune system and exocrine epithelia; thus, SS therapies should ideally achieve both local glandular and
systemic immunomodulation to fully treat the disease. Our initial focus is developing an effective treatment
regimen for SS-associated dry eye disease (DED) and systemic symptoms, using the male NOD mouse which
exhibits these disease manifestations of SS. We later explore efficacy in a model of autoimmune sialoadenitis
and systemic symptoms, the female NOR mouse. Topical treatments are currently used clinically to manage
symptoms of SS-associated DED, but these approaches are insufficient to suppress LG inflammation. Systemic
symptoms are also treated to limited success with general immunomodulatory agents which also lack sufficient
bioavailability to treat glandular inflammation. We hypothesize and test that a combined approach of
optimized local glandular plus systemic delivery of therapeutics is necessary to effectively treat both
glandular and extraglandular symptoms of SS. To achieve this, we use a versatile protein-polymer platform
comprised of elastin-like polypeptides (ELPs) that can be genetically fused to peptides/proteins in ways that
optimize their pharmacokinetics and bioactivity. Three Aims are proposed. Aim 1. Local LG
immunosuppression using Supra-LG Rapa ELP depots and Molecular targeting to ICAM-1. The
immunosuppressant, Rapamycin (Rapa), will be complexed to a depot-forming FKBP12-ELP fusion protein that
sequesters Rapa; this carrier will be further modified to target intracellular adhesion molecule 1 (ICAM-1)
increased in diseased LG in SS. In male NOD mice, efficacy will be assessed when delivered supra-LG towards
SS-associated DED and systemic disease. Aim 2. Th17 immunosuppression using systemic delivery of
extracellular IL-17 receptor ELPs. Elevated IL-17A is linked to SS pathogenesis. We develop soluble and
depot-ELP fusions expressing the extracellular domain of the IL-17 receptor (eIL17R) to form multivalent IL-17A-
sequestering nanoparticles for systemic delivery using subcutaneous (SC, flank) administration. In male NOD
mice, efficacy will be assessed in SS-associated DED and systemic symptoms. Aim 3: Efficacy of local and
systemic combination therapies in glandular and extraglandular symptoms of SS. Efficacy of combination
local + systemic treatments will be assessed using formulations delivered by supra-LG (5FV-Rapa) and SC
(soluble eIL17R-A192). Efficacy will be assessed both in male NOD mice (autoimmune dacryoadenitis/systemic
symptoms) and in female NOR mice (autoimmune sialoadenitis/systemic symptoms).
干燥综合征(SS)是一种以严重炎症和功能丧失为主要表现的自身免疫性疾病
泪腺(LG)和/或唾液腺(SG)的炎症,导致严重的干眼症和口干。SS患者也表现出
腺外系统症状,包括自身抗体的产生、内脏器官炎症和
B细胞淋巴瘤风险增加发病机制是复杂的,涉及激活的
因此,SS治疗应该理想地实现局部腺体和
全身免疫调节以充分治疗疾病。我们最初的重点是开发有效的治疗方法
使用雄性NOD小鼠,
表现出SS的这些疾病表现。我们稍后将探讨自身免疫性涎腺炎模型的疗效
和全身症状,雌性NOR小鼠。局部治疗目前用于临床管理
这些方法可以治疗SS相关DED的症状,但这些方法不足以抑制LG炎症。系统性
用一般的免疫调节剂治疗这些症状也只能获得有限的成功
治疗腺体炎症的生物利用度。我们假设和测试,
为了有效地治疗这两种疾病,
SS的腺和腺外症状。为了实现这一目标,我们使用了一个多功能的蛋白质聚合物平台,
包括弹性蛋白样多肽(ELP),所述ELP可以以
优化其药代动力学和生物活性。提出了三个目标。目标1.当地LG
使用Supra-LG Rapa ELP库和分子靶向ICAM-1的免疫抑制。的
免疫抑制剂雷帕霉素(Rapa)将与形成贮库FKBP 12-ELP融合蛋白复合,
螯合Rapa;该载体将进一步修饰以靶向细胞内粘附分子1(ICAM-1)
SS组患病LG增加。在雄性NOD小鼠中,将评估当将超-LG递送至
SS相关DED和全身性疾病。目标二。Th 17免疫抑制,使用全身性递送
细胞外IL-17受体ELP。IL-17 A升高与SS发病机制有关。我们开发可溶性和
表达IL-17受体的胞外结构域(eIL 17 R)以形成多价IL-17 A-ELP融合物的库-ELP融合物
用于使用皮下(SC,侧腹)施用的全身递送的螯合纳米颗粒。男性NOD
在小鼠中,将在SS相关的DED和全身症状中评估功效。目标3:局部和局部
SS的腺和腺外症状的全身联合治疗。的疗效观察
将使用supra-LG(5 FV-Rapa)和SC递送的制剂评估局部+全身治疗
(可溶性eIL 17 R-A192)。将在雄性NOD小鼠(自身免疫性泪腺炎/全身性
症状)和雌性NOR小鼠(自身免疫性涎腺炎/全身症状)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sarah F Hamm-Alvarez其他文献
Sarah F Hamm-Alvarez的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sarah F Hamm-Alvarez', 18)}}的其他基金
Development of a novel tear-based biomarker assay for diagnosis of Parkinson's disease using RT-QuIC
使用 RT-QuIC 开发一种新型基于泪液的生物标志物检测方法来诊断帕金森病
- 批准号:
10227242 - 财政年份:2020
- 资助金额:
$ 59.23万 - 项目类别:
Development of a novel tear-based biomarker assay for diagnosis of Parkinson's disease using RT-QuIC
使用 RT-QuIC 开发一种新型基于泪液的生物标志物检测方法来诊断帕金森病
- 批准号:
10057848 - 财政年份:2020
- 资助金额:
$ 59.23万 - 项目类别:
Ad5 Fiber Entry and Trafficking in Lacrimal Acini
Ad5 纤维在泪腺泡中的进入和运输
- 批准号:
7394357 - 财政年份:2006
- 资助金额:
$ 59.23万 - 项目类别:
Ad5 Fiber Entry and Trafficking in Lacrimal Acini
Ad5 纤维在泪腺泡中的进入和运输
- 批准号:
7447508 - 财政年份:2006
- 资助金额:
$ 59.23万 - 项目类别:
Ad5 Fiber Entry and Trafficking in Lacrimal Acini
Ad5 纤维在泪腺泡中的进入和运输
- 批准号:
7797328 - 财政年份:2006
- 资助金额:
$ 59.23万 - 项目类别:
Ad5 Fiber Entry and Trafficking in Lacrimal Acini
Ad5 纤维在泪腺泡中的进入和运输
- 批准号:
7075776 - 财政年份:2006
- 资助金额:
$ 59.23万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 59.23万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 59.23万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 59.23万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 59.23万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 59.23万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 59.23万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 59.23万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 59.23万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 59.23万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 59.23万 - 项目类别:
Continuing Grant